Why the study?
Does combination therapy with flecainide and metoprolol reduce symptomatic recurrences in patients with a recent episode of paroxysmal or persistent atrial fibrillation?
Does combination therapy with flecainide and metoprolol reduce symptomatic recurrences in patients with a recent episode of paroxysmal or persistent atrial fibrillation?
Combination therapy with flecainide and metoprolol significantly reduces symptomatic recurrences and improves quality of life compared to flecainide alone in patients with persistent atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May reduce AF recurrences vs flecainide alone in persistent cases; leaves open need for larger RCTs before practice change.
AIMS: Atrial fibrillation (AF) affects ∼2% of the total population. In order to prevent AF recurrences, many anti-arrhythmic drugs are currently available, but most of them are burdened by serious side effects and suboptimal efficacy. The aim of the present study was to test efficacy and safety of a combination of flecainide and metoprolol in preventing AF clinical recurrences. METHODS AND RESULTS: This study is a monocentric, prospective, randomized, open-blinded trial on 173 patients with a recent episode of paroxysmal or persistent AF. Patients were randomized into group A (flecainide + metoprolol; n = 80), group B (flecainide only; n = 72), or group C (metoprolol only; n = 21). Main exclusion criteria were recent acute coronary syndrome, heart failure New York Heart Association class III-IV, left ventricular ejection fraction <0.40, atrioventricular conduction disorders, and severe bradycardia. Primary endpoint was symptomatic recurrence over 1-year follow-up. Secondary endpoint was quality of life (QoL) over 1-year follow-up, as assessed by the SF-36 and Atrial Fibrillation Severity Scale questionnaires. Combination therapy with flecainide and metoprolol significantly reduced recurrences at 1-year follow-up when compared with flecainide alone in the whole population (66.7 vs. 46.8%; P < 0.001) and in patients with persistent AF (71.1 vs. 43.6%; P = 0.025) while adding beta-blocker therapy to paroxysmal AF showed no benefit over IC anti-arrhythmic drug-only. Patients randomized to combination therapy experienced a significant improvement of QoL when compared with those assigned to a flecainide-only regimen irrespective of AF type. CONCLUSION: Flecainide-metoprolol combination therapy improves effectiveness of rhythm control in persistent symptomatic AF and increases tolerability, with a concomitant reduction of side effects and a better compliance.
No takes yet. Share an insight, caveat, or question.
Capucci et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: